The short version of circadian clock fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-15 and is reviewed periodically as new material appears.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
== International presence == Viscofan exports a large part of its products to other markets and is currently present in over 100 countries. It has production centers in 13 countries and maintains commercial offices in 15 countries.
Potassium (19K) has 25 known isotopes from 34K to 57K as well as 31K, as well as an unconfirmed report of 59K. Three of those isotopes occur naturally: the two stable forms 39K (93.26%) and 41K (6.72%), and the long-lived radioisotope 40K (0.012%). Naturally occurring radioactive 40K decays with a half-life of 1.248×109 years. 89% of those decays are to stable 40Ca by beta decay, whilst 11% are to 40Ar by either electron capture or positron emission. This latter decay branch has produced an isotopic abundance of argon on Earth which differs greatly from that seen in gas giants and stellar spectra. 40K has the longest known half-life for any positron-emitting nuclide. The long half-life of this primordial radioisotope is caused by a highly spin-forbidden transition: 40K has a nuclear spin of 4, while both of its decay daughters are even–even isotopes with spins of 0. 40K occurs in natural potassium in sufficient quantity that large bags of potassium chloride commercial salt substitutes can be used as a radioactive source for classroom demonstrations. 40K is the largest source of natural radioactivity in healthy animals and humans, greater even than 14C. In a human body of 70 kg mass, about 4,300 nuclei of 40K decay per second. The decay of 40K to 40Ar is used in potassium-argon dating of rocks. Minerals are dated by measurement of the concentration of potassium and the amount of radiogenic 40Ar that has accumulated. 40K has also been extensively used as a radioactive tracer in studies of weathering.
=== In Vietnam === The clinical trials of the vaccine in Vietnam are completely sponsored and funded by Vinbiocare, a Vingroup subsidiary. On 2 August, Vinbiocare received regulatory approval to start a clinical trial of its COVID-19 vaccine candidate in Vietnam. The company will coordinate with the Ministry of Health to carry out Phase I-III clinical trials of VBC-COV19-154 vaccine on 21,000 adults in three phases in August 2021. The clinical trial Phase 1 will recruit 100 volunteers to evaluate the safety, tolerability, and initial assessment of immunogenicity of the vaccine. The clinical trial Phase 2 enrolled 300 volunteers at designated medical facilities in multiple provinces, while the third phase of human trials is expected to involve 20,600 volunteers, including phase 3a (600 volunteers) and 3b (20,000 volunteers). Those receiving placebo will receive active vaccine after 6 months, while all participants will be followed up for 1 year. In December 2021, the company plans to complete and submit procedures to the Ministry of Health, applying for an emergency authorization in Vietnam.
== Further reading == Tai CH, Lee NC, Chien YH, Byrne BJ, Muramatsu SI, Tseng SH, et al. (February 2022). "Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency". Molecular Therapy. 30 (2): 509–518. doi:10.1016/j.ymthe.2021.11.005. PMC 8822132. PMID 34763085.{{cite journal}}: CS1 maint: overridden setting (link)
== Genetic methods == Experimental analysis of proteins typically requires expression and purification of proteins. Expression is achieved by manipulating DNA that encodes the protein(s) of interest. Hence, protein analysis usually requires DNA methods, especially cloning. Some examples of genetic methods include conceptual translation, Site-directed mutagenesis, using a fusion protein, and matching allele with disease states. Some proteins have never been directly sequenced, however by translating codons from known mRNA sequences into amino acids by a method known as conceptual translation. (See genetic code.) Site-directed mutagenesis selectively introduces mutations that change the structure of a protein. The function of parts of proteins can be better understood by studying the change in phenotype as a result of this change. Fusion proteins are made by inserting protein tags, such as the His-tag, to produce a modified protein that is easier to track. An example of this would be GFP-Snf2H which consists of a protein bound to a green fluorescent protein to form a hybrid protein. By analyzing DNA alleles can be identified as being associated with disease states, such as in calculation of LOD scores.
Sources: en.wikipedia.org
== NASA partnership == In 1962, the company's research laboratories won a contract from NASA to develop the food and waste management system for Project Gemini. The company later developed freeze-dried ice cream in 1968 under contract to NASA for the Apollo missions. Returning to work with NASA under the Johnson Space Center's Advanced Exploration Systems Logistics Reduction and Repurposing project in 2021, Whirlpool developed a zero-gravity refrigerator in partnership with Purdue University and Air Squared to investigate long term food storage for deep space exploration.
== Recalls and safety corrections == In 2014, Tandem recalled selected lots of t:slim cartridges because leaks could cause too much or too little insulin to be delivered. In 2024, the FDA classified a correction of version 2.7 of the iOS t:connect app as a Class I recall. Repeated app crashes and automatic relaunches could increase Bluetooth communication, drain a connected t:slim X2 battery and interrupt insulin delivery. The action covered 85,863 distributed app installations; the FDA reported 224 injuries and no deaths as of April 15, 2024. Tandem released updated app versions and advised users to monitor pump batteries. In April 2025, the FDA classified a correction of Control-IQ+ software version 7.9 as a Class I recall. A defect affecting 85 pumps could incorrectly interpolate glucose values after gaps in CGM data and cause too much or too little insulin to be delivered. Tandem instructed affected users to turn off Control-IQ+ until the software was corrected. Later in 2025, Tandem issued two further corrections that the FDA classified as Class I recalls. One covered 171,750 t:slim X2 pumps whose speakers could fail and stop insulin delivery; the company reported 59 injuries and no deaths. The other covered 17,745 Mobi pumps that could falsely detect vibration-motor failure and enter a non-operational state, stopping insulin delivery and CGM sessions. Tandem directed users to install corrected pump software.
== External links == Actin Staining Techniques (Live and Fixed Cell Staining) Eukaryotic Linear Motif resource motif class LIG_Actin_RPEL_3 Eukaryotic Linear Motif resource motif class LIG_Actin_WH2_1 Eukaryotic Linear Motif resource motif class LIG_Actin_WH2_2 3D macromolecular structures of actin filaments from the EM Data Bank(EMDB)
==== Host-targeting antivirals ==== Unlike DAAs that target viral proteins, host targeting antivirals (HTAs) inhibit host proteins involved in viral infection and replication. Many viruses utilize common processes to enter host cells and create viral replicates. Because HTAs target processes that are commonly conserved by multiple viral strains, HTAs have the potential to be used as broad spectrum antivirals (BSAs) with activity against multiple viral infections. Processes that are common targets of HTAs include viral entry into the host cell, viral replication, nuclear import and export, and viral release from the host cell. HTAs are attractive to physicians because they have a higher genetic barrier to resistance than DAAs. Host genomes are generally more stable than viral genomes (particularly RNA viruses that are known for their high genetic instability and rapid mutation rate) due to the presence of DNA polymerase proofreading capabilities that corrects point mutations in genetic replication. Taken together, the genetic barrier of HTAs and stability of host cell genomes increase the amount of time it takes for resistance to develop to HTAs. Commonly used FDA-approved HTAs include maraviroc, and interferon. Maraviroc binds to the CCR5 receptor on the surface of host cells. The CCR5 receptor is internalized, and HIV is unable to bind to it, thus inhibiting HIV entry into host macrophages and T-cells.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.